Biochemopreventive therapy for patients with premalignant lesions of the head and neck and p53 gene expression

J Natl Cancer Inst. 2000 Jan 5;92(1):69-73. doi: 10.1093/jnci/92.1.69.

Authors

D M Shin¹, L Mao, V M Papadimitrakopoulou, G Clayman, A El-Naggar, H J Shin, J J Lee, J S Lee, A Gillenwater, J Myers, S M Lippman, W N Hittelman, W K Hong

Affiliation

¹ Department of Thoracic/Head and Neck Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

PMID: 10620636
DOI: 10.1093/jnci/92.1.69

No abstract available

Publication types

Clinical Trial
Clinical Trial, Phase II
Research Support, U.S. Gov't, P.H.S.

MeSH terms

Anticarcinogenic Agents / therapeutic use*
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Cell Transformation, Neoplastic / drug effects*
Cell Transformation, Neoplastic / pathology
Gene Expression Regulation, Neoplastic / drug effects*
Head and Neck Neoplasms / metabolism
Head and Neck Neoplasms / pathology
Head and Neck Neoplasms / prevention & control*
Humans
Immunohistochemistry
Interferon-alpha / administration & dosage
Isotretinoin / administration & dosage
Mutation / drug effects*
Precancerous Conditions / drug therapy*
Precancerous Conditions / metabolism
Precancerous Conditions / pathology
Prospective Studies
Treatment Outcome
Tumor Suppressor Protein p53 / genetics
Tumor Suppressor Protein p53 / metabolism*
Vitamin E / administration & dosage

Substances

Anticarcinogenic Agents
Interferon-alpha
Tumor Suppressor Protein p53
Vitamin E
Isotretinoin

Grants and funding